ProCE Banner Activity

Not Always a Last Resort: The Evidence for Basal Insulin

Clinical Thought

A leading expert reviews the utility of basal insulin for patients with type 2 diabetes and ongoing work in the development of newer, more convenient therapies.

Released: July 17, 2023

Share

Faculty

Richard E. Pratley

Richard E. Pratley, MD

AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins School of Medicine
Orlando, Florida

Provided by

Provided by Clinical Care Options, LLC in partnership with the Endocrine Society

ProCE Banner

Supporters

This activity is supported by an educational grant from Novo Nordisk. 

Novo Nordisk

Partners

Endocrine Society

ProCE Banner

Faculty Disclosure

Primary Author

Richard E. Pratley, MD

AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins School of Medicine
Orlando, Florida

Richard E. Pratley, MD: researcher (paid to institution): Dompe, Hanmi Pharmaceutical, Novo Nordisk; consultant/speaker (paid to institution): Bayer AG, Dexcom, Endogenex, Gasherbrum Bio, Hengrui, Lilly, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceutical, Sun Pharmaceutical Industries.